Benbrahim Zineb, Massard Christophe, El Mesbahi Omar
CHU Hassan-II, service d'oncologie médicale, Fès, Maroc.
Bull Cancer. 2011 Dec;98(12):1447-54. doi: 10.1684/bdc.2011.1493.
Angiogenesis is crucial for the growth and metastasis of many cancers. A series of new inhibitors of angiogenesis are now in intensive development. Recent preclinical studies suggest that frequent administration of certain conventional cytotoxic agents at low doses increases their putative antiangiogenic activity. Moreover, many clinical trials confirm efficacy of this metronomic chemotherapy in terms of clinical benefice and survival prolongation. Combining metronomic chemotherapy with hormonotherapy, angiogenesis inhibitors and radiotherapy increases efficacy. Many biomarkers are used to predict optimal drugs and appropriate use of them. This review describes experimental and clinical studies published and discuss its potential uses and limits.
血管生成对许多癌症的生长和转移至关重要。一系列新型血管生成抑制剂目前正处于深入研发阶段。近期的临床前研究表明，低剂量频繁给予某些传统细胞毒性药物可增强其假定的抗血管生成活性。此外，许多临床试验证实了这种节拍化疗在临床获益和延长生存期方面的疗效。将节拍化疗与激素疗法、血管生成抑制剂及放疗相结合可提高疗效。许多生物标志物被用于预测最佳药物及其合理使用。本综述描述了已发表的实验和临床研究，并讨论了其潜在用途和局限性。
